Renaissance Technologies LLC grew its position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Rating) by 15.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,666,096 shares of the biopharmaceutical company’s stock after acquiring an additional 226,600 shares during the quarter. Renaissance Technologies LLC owned 1.02% of Sangamo Therapeutics worth $8,164,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds have also modified their holdings of the company. Allspring Global Investments Holdings LLC raised its stake in Sangamo Therapeutics by 31.5% during the third quarter. Allspring Global Investments Holdings LLC now owns 10,205 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 2,445 shares in the last quarter. New Harbor Financial Group LLC purchased a new stake in shares of Sangamo Therapeutics during the 3rd quarter valued at about $51,000. Fox Run Management L.L.C. bought a new position in shares of Sangamo Therapeutics in the 3rd quarter valued at about $59,000. Cookson Peirce & Co. Inc. purchased a new position in Sangamo Therapeutics in the third quarter worth about $59,000. Finally, Aigen Investment Management LP bought a new stake in Sangamo Therapeutics during the third quarter worth approximately $62,000. 59.34% of the stock is owned by hedge funds and other institutional investors.
Sangamo Therapeutics Stock Performance
NASDAQ SGMO opened at $2.49 on Wednesday. Sangamo Therapeutics, Inc. has a 12 month low of $2.46 and a 12 month high of $6.42. The company’s 50-day moving average price is $3.21 and its 200-day moving average price is $3.97.
Wall Street Analyst Weigh In
SGMO has been the subject of a number of recent research reports. HC Wainwright dropped their target price on Sangamo Therapeutics from $25.00 to $15.00 and set a “buy” rating for the company in a report on Friday, March 3rd. Wells Fargo & Company dropped their price objective on shares of Sangamo Therapeutics from $20.00 to $15.00 and set an “overweight” rating for the company in a research note on Wednesday, January 4th. Wedbush raised shares of Sangamo Therapeutics from a “neutral” rating to an “outperform” rating and set a $16.00 target price on the stock in a research note on Monday, February 27th. Royal Bank of Canada dropped their price target on shares of Sangamo Therapeutics from $22.00 to $13.00 and set an “outperform” rating for the company in a research note on Thursday, February 23rd. Finally, Bank of America lowered shares of Sangamo Therapeutics from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $8.00 to $5.00 in a research report on Friday, January 6th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, Sangamo Therapeutics has an average rating of “Moderate Buy” and an average target price of $13.83.
Sangamo Therapeutics Profile
Sangamo Therapeutics, Inc is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases.
- Get a free copy of the StockNews.com research report on Sangamo Therapeutics (SGMO)
- Under-the-Radar Azul SA Takes Flight on Robust Travel Demand
- Market Gets “Powelled”: S&P 500 Confirms Resistance
- Rivian Plummets, But Is This 2023’s Greatest Buying Opportunity?
- Ulta Insiders Hold Tight: Sell-Siders Buy
- Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.